2. Search Result
Search Result
Results for "

Neurodegeneration

" in MedChemExpress (MCE) Product Catalog:

115

Inhibitors & Agonists

5

Screening Libraries

1

Fluorescent Dyes

1

Biochemical Assay Reagents

7

Peptides

1

Inhibitory Antibodies

20

Natural
Products

7

Isotope-Labeled Compounds

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0250
    Lamivudine
    15+ Cited Publications

    BCH-189

    		 HIV Reverse Transcriptase HBV Infection Cancer
    Lamivudine (BCH-189) is an orally active nucleoside reverse transcriptase inhibitor (NRTI). Lamivudine can inhibit HIV reverse transcriptase 1/2 and also the reverse transcriptase of hepatitis B virus. Lamivudine salicylate can penetrate the CNS .
    Lamivudine
  • HY-N0013
    Vitexin
    Maximum Cited Publications
    12 Publications Verification

    		 Autophagy Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
    Vitexin is a c-glycosylated flavone, and is found in various medicinal plants species such as Trigonella foenum-graecum Linn. Vitexin has a wide range of pharmacological effects, including anti-oxidant, anti-cancer, anti-inflammatory, anti-hyperalgesic, and neuroprotective effects .
    Vitexin
  • HY-12355
    Siponimod
    5+ Cited Publications

    BAF-312

    		 LPL Receptor Neurological Disease Inflammation/Immunology
    Siponimod (BAF-312) is an orally active and selective sphingosine-1-phosphate (S1P) receptor modulator. Siponimod is selective for S1P1 and S1P5 over S1P2, S1P3, and S1P4, with EC50s of 0.4, 0.98, >10000, >1000, and 750 nM, respectively. Siponimod can be used for multiple sclerosis (MS) research - .
    Siponimod
  • HY-128850
    N-Acetyl-D-mannosamine

    N-Acetylmannosamine; ManNAc

    		 Endogenous Metabolite Cardiovascular Disease Neurological Disease
    N-Acetyl-D-mannosamine (ManNAc) is an oral active sialic acid precursor that can prevent hypertension by increasing sialylation of IgG, making it a promising candidate for cardiovascular disease research. Additionally, N-Acetyl-D-mannosamine can activate hypocretin (HCRT) gene expression in orexin neurons and improve neurodegeneration caused by aging, offering potential avenues for research in neurological disorders .
    N-Acetyl-D-mannosamine
  • HY-B1028
    Pantethine
    5 Publications Verification

    D-Pantethine; LBF disulfide

    		 Endogenous Metabolite SARS-CoV Cardiovascular Disease Neurological Disease Inflammation/Immunology Endocrinology Cancer
    Pantethine is an orally active lipid-lowering agent. Pantethine has anti-tumor, anti-inflammatory and anti-SARS-COV virus activities. Pantethine is also a neuroprotective agent. Pantethine can be used in the study of Alzheimer's disease, Parkinson's disease, major depression, systemic sclerosis and pantothenate kinase-related neurodegeneration .
    Pantethine
  • HY-15176A
    Pyridostatin hydrochloride
    Maximum Cited Publications
    34 Publications Verification

    RR82 hydrochloride

    		 DNA/RNA Synthesis G-quadruplex Flavivirus Src Virus Protease Cancer
    Pyridostatin (RR82) hydrochloride is a G-quadruplex DNA stabilizing agent (Kd=490 nM) and can target DNA and RNA G4s in cells. Pyridostatin hydrochloride promotes growth arrest in human cancer cells by inducing replication- and transcription-dependent DNA damage. Pyridostatin hydrochloride targets the proto-oncogene Src. Pyridostatin hydrochloride reduced SRC protein levels and SRC-dependent cellular motility in human breast cancer cells .
    Pyridostatin hydrochloride
  • HY-15176
    Pyridostatin

    RR82

    		 G-quadruplex Cancer
    Pyridostatin (RR82) is a G-quadruplex DNA stabilizing agent (Kd=490 nM) and can target DNA and RNA G4s in cells. Pyridostatin promotes growth arrest in human cancer cells by inducing replication- and transcription-dependent DNA damage. Pyridostatin targets the proto-oncogene Src. Pyridostatin reduced SRC protein levels and SRC-dependent cellular motility in human breast cancer cells .
    Pyridostatin
  • HY-100591
    SirReal2
    2 Publications Verification

    		 Sirtuin Neurological Disease Inflammation/Immunology Cancer
    SirReal2 is a potent, isotype-selective Sirt2 inhibitor with an IC50 value of 140 nM and has very little effect on the activities of Sirt3-5. SirReal2 leads to tubulin hyperacetylation in HeLa cells and induces destabilization of the checkpoint protein BubR1. SirReal2 combined with VS-5584 (HY-16585) suppresses tumor growth and extends the survival rate of mice in tumor xenograft model. SirReal2 is is promising for research of cancer, inflammation and neurodegeneration .
    SirReal2
  • HY-59291
    Levacetylleucine

    N-Acetyl-L-leucine

    		 Amino Acid Derivatives Neurological Disease Metabolic Disease Inflammation/Immunology
    Levacetylleucine (N-acetyl-L-leucine), an orally bioavailable and brain-penetrant compound, is an acetylated derivative of amino acid Leucine. Levacetylleucine is the active form of N-acetyl-leucine (NAL). Levacetylleucine attenuates neuronal death and neuroinflammation in the cortical tissue of mice. Levacetylleucine also potentially improves ameliorates lysosomal and metabolic dysfunction. Levacetylleucine improves compensation of postural symptoms after unilateral chemical labyrinthectomy (UL) in rats. Levacetylleucine is promising for research of neurological manifestations of Niemann-Pick disease type C, traumatic brain injury and neurodegeneration prevention .
    Levacetylleucine
  • HY-13010
    Laquinimod
    2 Publications Verification

    ABR-215062

    		 NF-κB Apoptosis Inflammation/Immunology
    Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator which prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod has the potential for relapsing remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research .
    Laquinimod
  • HY-44170
    Pantothenate kinase-IN-2
    2 Publications Verification

    		 PANK Neurological Disease Metabolic Disease
    Pantothenate kinase-IN-2 is a pantothenate kinase inhibitor with IC50 values of 92 nM for PanK2, 70 nM for PanK1β, and 25 nM for PanK3. Pantothenate kinase-IN-2 can bind specifically to the ATP-PanK3 complex and block CoA biosynthesis. Pantothenate kinase-IN-2 can be used for the research of pank-associated neurodegeneration and type 2 diabetes .
    Pantothenate kinase-IN-2
  • HY-15176B
    Pyridostatin TFA
    Maximum Cited Publications
    34 Publications Verification

    RR82 TFA

    		 DNA/RNA Synthesis G-quadruplex Flavivirus Src Virus Protease Cancer
    Pyridostatin (RR82) TFA is a G-quadruplex (G4) inducer/stabilizer with a Kd of 490 nM. Pyridostatin TFA also acts as an inhibitor of Zika virus (ZIKV) NS2B-NS3 protease, with an IC50 of 11.0 μM. Pyridostatin TFA interacts with G-quadruplex structures, regulates the expression of SRC and SUB1, and induces replication- and transcription-dependent DNA damage, growth arrest, and genomic instability. Pyridostatin TFA exhibits antiproliferative and antiviral activities. Pyridostatin TFA can be used in studies related to breast cancer, cervical cancer, and Zika virus infection .
    Pyridostatin TFA
  • HY-15976
    P7C3
    5+ Cited Publications

    		 Others Neurological Disease
    P7C3 is an orally bioavailable and blood-brain barrier penetrant aminopropyl carbazole, with neuroprotective effects. P7C3 can be used for the research of neurodegenerative diseases, including Parkinson's disease .
    P7C3
  • HY-N4110
    Friedelin
    1 Publications Verification

    		 Cytochrome P450 NF-κB Interleukin Related Neurological Disease Metabolic Disease Inflammation/Immunology
    Friedelin is derived from the leaves of Maytenus ilicifolia (Mart). Friedelin is an orally active non-competitive inhibitor of CYP3A4, with IC50 and Ki values of 10.79 μM and 6.16 μM, respectively. Friedelin is also a competitive inhibitor of CYP2E1, with IC50 and Ki values of 22.54 μM and 18.02 μM, respectively. Friedelin can be used in research related to inflammation, neurological diseases, and metabolic disorders .
    Friedelin
  • HY-101499
    GKT136901
    4 Publications Verification

    		 NADPH Oxidase Neurological Disease Metabolic Disease Inflammation/Immunology
    GKT136901 is a potent, selective and orally active inhibitor of NADPH oxidase (NOX1/4), with Kis of 160 and 165 nM, respectively. GKT136901 is also a selective and direct scavenger of peroxynitrite. GKT136901 can be used for the research of diabetic nephropathy, stroke, and neurodegeneration. GKT136901 also has anti-inflammatory activity .
    GKT136901
  • HY-111793
    NUCC-390
    5+ Cited Publications

    		 CXCR Neurological Disease
    NUCC-390 is a novel and selective small-molecule CXCR4 receptor agonist. NUCC-390 induces internalization of CXCR4 receptors and acts in an opposite way of AMD3100 (HY-10046) . NUCC-390 promotes nerve recovery of function after neurodegeneration in vivo .
    NUCC-390
  • HY-P991734
    VHB937

    		TREM receptor Syk Calcium Channel Neurological Disease Inflammation/Immunology
    VHB937 is a potent and selective TREM2 agonist, a human monoclonal antibody, with sub-nanomolar affinity. VHB937 enhances TREM2 surface expression and downstream signaling, such as Syk phosphorylation and calcium mobilization. VHB937 exhibits robust neuroprotective effects in vivo, significantly reducing pathology and pro-inflammatory markers across a broad range of animal models of neuroinflammation and neurodegeneration. VHB937 can be used for neurodegenerative diseases research .
    VHB937
  • HY-136311
    NCT-504

    		PI5P4K Neurological Disease
    NCT-504 is a selective allosteric inhibitor of PIP4Kγ, with an IC50 of 15.8 μM. NCT-504 is potential for the research of Huntington's disease .
    NCT-504
  • HY-P10368
    P110 heptapeptide

    		Dynamin Reactive Oxygen Species (ROS) Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology
    P110 heptapeptide is a peptide inhibitor of the Drp1-Fis1 interaction. P110 heptapeptide has anti-inflammatory, immunomodulatory, mitochondrial protective, and neuroprotective activities. Without blocking the physiological functions of Drp1, P110 heptapeptide reduces pathological functions in many models of neurodegeneration, ischemia, and sepsis. P110 heptapeptide can be used for research on neurological and inflammatory diseases .
    P110 heptapeptide
  • HY-149555
    DNL343

    		Eukaryotic Initiation Factor (eIF) Neurological Disease
    DNL343 is a potent, selective, orally active and brain-penetrant activator of eukaryotic initiation factor eIF2B. DNL343 inhibits the activity of the integrated stress response (ISR) in the central nervous system (CNS) and reverses neurodegeneration and neuroinflammation. DNL343 also prevents motor dysfunction and premature death in eIF2B loss-of-function (LOF) mutant mice. DNL343 can be used in the study of neurodegenerative diseases .
    DNL343
  • HY-106353
    Smilagenin
    1 Publications Verification

    		 mAChR Endogenous Metabolite Neurological Disease
    Smilagenin (SMI) is a small-molecule steroidal sapogenin from Anemarrhena asphodeloides and Pelargonium hortorum widely used in traditional Chinese medicine for treating chronic neurodegeneration diseases . Smilagenin (SMI) improves memory of aged rats by increasing the muscarinic receptor subtype 1 (M1)-receptor density . Smilagenin (SMI) attenuates Aβ(25-35)-induced neurodegenerationvia stimulating the gene expression of brain-derived neurotrophic factor, may represents a novel therapeutic strategy for AD .
    Smilagenin
  • HY-113410
    3-Methylglutaric acid

    		Na+/K+ ATPase Mitochondrial Metabolism Reactive Oxygen Species (ROS) Neurological Disease Metabolic Disease
    3-Methylglutaric acid is a non-selective inhibitor of mitochondrial function and Na +, K +-ATPase, with an inhibition rate of 30% on rat cortical synaptosomal Na +, K +-ATPase. 3-Methylglutaric acid can induce reactive oxygen species (ROS) generation, thereby causing oxidative damage and inhibiting mitochondrial redox potential and ion pump function of cell membranes. 3-Methylglutaric acid can be used to study the neuropathological mechanisms of metabolic diseases and the role of oxidative stress-mediated neuronal damage in neurodegeneration .
    3-Methylglutaric acid
  • HY-P2280
    TAT-P110

    P110

    		 Dynamin Neurological Disease Inflammation/Immunology
    TAT-P110, a peptide inhibitor of Drp1-Fis1 interaction, reduces pathology in numerous models of neurodegeneration, ischemia, and sepsis without blocking the physiological functions of Drp1 .
    TAT-P110
  • HY-109086
    Edicotinib
    3 Publications Verification

    JNJ-40346527; JNJ-527

    		 c-Fms Neurological Disease Inflammation/Immunology Cancer
    Edicotinib (JNJ-40346527) is a potent, selective, brain penetrant and orally active colony-stimulating factor-1 receptor (CSF-1R) inhibitor with an IC50 of 3.2 nM. Edicotinib exhibits less inhibitory effects on KIT and FLT3 with IC50 values of 20 nM and 190 nM, respectively . Edicotinib limits microglial expansion and attenuates microglial proliferation and neurodegeneration in mice. Edicotinib has the potential for Alzheimer’s disease and rheumatoid arthritis research .
    Edicotinib
  • HY-160229
    ssRNA40 sodium

    R-1075 sodium

    		 Toll-like Receptor (TLR) MyD88 Caspase Reactive Oxygen Species (ROS) Autophagy Pyroptosis HIV Infection Neurological Disease
    ssRNA40 sodium (R-1075 sodium) is a single-stranded RNA40 derived from HIV-1. ssRNA40 sodium activates the TLR7, TLR8, TLR2, RIG-I, MDA5, MyD88, Caspase-3, IRE1α, NLRP3 inflammasome and IRF7 signaling pathways. ssRNA40 sodium alters mRNA expression in neutrophils, induces pro-inflammatory cytokines, ROS, autophagy (autophagy), pyroptosis (pyroptosis), neuronal death, neurodegeneration, aggregate formation and NK cell activation. ssRNA40 sodium activates the expression of CD62L, CD11b, CD69, MX1, OAS1, ATG7, LC3B and XBP1 in immune cell and neuronal populations. ssRNA40 sodium causes cortical neuron loss and axonal damage in mice in a TLR7-dependent manner. ssRNA40 sodium can be used in research on HIV-1 infection, neurodegeneration, COVID-19 and HIV-associated neurological disorders .
    ssRNA40 sodium
  • HY-113285
    Ureidopropionic acid

    3-Ureidopropionic acid

    		 Oxidative Phosphorylation Metabolic Disease
    Ureidopropionic acid is a mitochondrial respiratory chain complex V inhibitor that selectively inhibits the activity of mitochondrial respiratory chain complex V, with no effect on respiratory chain complexes I-IV or mitochondrial fatty acid β-oxidation. Ureidopropionic acid induces the production of reactive oxygen species, delayed elevation of intracellular calcium concentration, secondary energy-dependent excitotoxicity and neurodegeneration in neurons. Ureidopropionic acid promotes neuropathological changes by impairing mitochondrial energy metabolism, oxidative stress and excitotoxicity pathways. Ureidopropionic acid can be used in studies related to 3-ureidopropionase deficiency and severe propionic aciduria .
    Ureidopropionic acid
  • HY-126415
    Magnesium Lithospermate B
    1 Publications Verification

    		 Na+/K+ ATPase Cardiovascular Disease Neurological Disease Inflammation/Immunology
    Magnesium Lithospermate B, is a derivative of caffeic acid tetramer and an inhibitor of Na+/K+ ATPase, which can be extracted from Salviae miltiorrhizae. Magnesium Lithospermate B is widely used for the research of cardiovascular diseases, and it can protect against glucose-induced intracellular oxidative damage. Magnesium Lithospermate B also suppresses neuroin?ammation and attenuates neurodegeneration .
    Magnesium Lithospermate B
  • HY-136390
    ML417
    1 Publications Verification

    		 Dopamine Receptor Neurological Disease
    ML417 is a selective and brain penetrant D3 dopamine receptor (D3R) agonist, with an EC50 of 38 nM. ML417 potently promotes D3R-mediated β-arrestin translocation, G protein mediated signaling, and pERK phosphorylation with minimal effects on other GPCR-mediated signaling. ML417 exhibits neuroprotection against toxin-induced neurodegeneration of dopaminergic neurons .
    ML417
  • HY-15176C
    Pyridostatin trihydrochloride
    Maximum Cited Publications
    34 Publications Verification

    RR82 trihydrochloride

    		 DNA/RNA Synthesis G-quadruplex Flavivirus Src Virus Protease Cancer
    Pyridostatin (RR82) trihydrochloride is a G-quadruplex (G4) inducer/stabilizer with a Kd of 490 nM. Pyridostatin trihydrochloride also acts as an inhibitor of Zika virus (ZIKV) NS2B-NS3 protease, with an IC50 of 11.0 μM. Pyridostatin trihydrochloride interacts with G-quadruplex structures, regulates the expression of SRC and SUB1, and induces replication- and transcription-dependent DNA damage, growth arrest, and genomic instability. Pyridostatin trihydrochloride exhibits antiproliferative and antiviral activities. Pyridostatin trihydrochloride can be used in studies related to breast cancer, cervical cancer, and Zika virus infection .
    Pyridostatin trihydrochloride
  • HY-137840
    Hippuryl-L-phenylalanine

    		Carboxypeptidase Cancer
    Hippuryl-L-phenylalanine is a substrate of carboxypeptidase. Carboxypeptidase is a protease enzyme that related with obesity, epilepsy and neurodegeneration. Hippuryl-L-phenylalanine can be used for the determination of carboxypeptidase activity .
    Hippuryl-L-phenylalanine
  • HY-111793A
    NUCC-390 dihydrochloride
    5+ Cited Publications

    		 CXCR Neurological Disease
    NUCC-390 dihydrochloride is a novel and selective small-molecule CXCR4 receptor agonist. NUCC-390 dihydrochloride induces internalization of CXCR4 receptors and acts in an opposite way of AMD3100 (HY-10046) . NUCC-390 dihydrochloride promotes nerve recovery of function after neurodegeneration in vivo .
    NUCC-390 dihydrochloride
  • HY-P1707A
    Tau protein (592-597), human TFA

    		Tau Protein Neurological Disease
    Tau protein (592-597), human TFA is a peptide fragment of human Tau protein. The dysfunction of Tau protein is involved in neurodegeneration and dementia .
    Tau protein (592-597), human TFA
  • HY-122381
    Kyotorphin
    1 Publications Verification

    		 Bacterial Endogenous Metabolite Neurological Disease
    Kyotorphin is an endogenou neuroactive dipeptide with analgesic properties. Kyotorphin possesses anti-inflammatory and antimicrobial activity. Kyotorphin levels in cerebro-spinal fluid correlate negatively with the progression of neurodegeneration in Alzheimer's Disease patients .
    Kyotorphin
  • HY-117709
    BRD6688

    		HDAC Neurological Disease
    BRD6688 is a selective HDAC2 inhibitor. BRD6688 increases H4K12 and H3K9 histone acetylation in primary mouse neuronal cells. BRD6688 crosses the blood brain barrier and rescues the memory defects associated with p25 induced neurodegeneration in contextual fear conditioning in a CK-p25 mouse model .
    BRD6688
  • HY-148184
    USP1-IN-3

    		Deubiquitinase Cancer
    USP1-IN-3 is a selective USPI inhibitor. USP1-IN-3 inhibits USPI-UAFI with an IC50 value of ＜30 nM. USP1-IN-3 can be used for the research of cancer .
    USP1-IN-3
  • HY-135869
    Mito-apocynin (C11)
    3 Publications Verification

    		 Mitochondrial Metabolism Neurological Disease
    Mito-apocynin (C11), an orally active mitochondria-targeted triphenylphosphonium (TPP)-based compound, is synthesized by conjugating the Apocynin moiety with a TPP + cation. Mito-apocynin (C11) selectively targets mitochondria, and shows neuroprotective effect. Mito-apocynin (C11) prevents hyposmia and corrects deficits in motor function .
    Mito-apocynin (C11)
  • HY-159509
    Claziprotamidum

    Claziprotamide; BBP-671

    		 PANK Neurological Disease Metabolic Disease
    Claziprotamidum (Claziprotamide; BBP-671) is a panthothenate kinase (PANK) activator with oral activity and blood-brain barrier permeability. Claziprotamidum binds to and activates all PANK isoforms, with the highest affinity for PANK3 (KD = 97 pM; IC50 = 1.39 nM). Claziprotamidum increases the intracellular biosynthesis of Coenzyme A (HY-128851) and restores mitochondrial function. Claziprotamidum can be used in the research of pantothenate kinase-associated neurodegeneration and propionic acidemia .
    Claziprotamidum
  • HY-109033
    Fosmetpantotenate

    RE-024

    		 Drug Intermediate Neurological Disease
    Fosmetpantotenate is a phosphopantothenic acid (PPA) precursor designed to release PPA intracellularly, leading to restoration of CoA levels. Fosmetpantotenate is used to research pantothenate kinase-associated neurodegeneration.
    Fosmetpantotenate
  • HY-124042
    K6PC-5
    4 Publications Verification

    		 SphK Filovirus Infection Neurological Disease Inflammation/Immunology
    K6PC-5, a ceramide derivative, is a sphingosine kinase 1(SPHK1) activator and elicites a rapid transient increase in intracellular calcium levels. K6PC-5 has the potential for skin diseases involving abnormal keratinocyte, and neurodegeneration and virus infection research .
    K6PC-5
  • HY-150407
    TSPO ligand-1

    		Ligands for Target Protein for PROTAC Autophagy Others Neurological Disease Cancer
    TSPO ligand-1 is the ligand of AUTAC4 (HY-134640) that can be used in the synthesis of PROTACs. TSPO ligand-1 is a mitochondrial outer membrane transmembrane structural domain protein can bind to AUTAC4 and regulate mitochondrial autophagy to promote targeted mitochondrial renewal. TSPO ligand-1 is also involved in the transport of cholesterol from the outer to inner mitochondrial membrane and serves as a sensitive biomarker of brain injury and neurodegeneration .
    TSPO ligand-1
  • HY-101499A
    GKT136901 hydrochloride
    4 Publications Verification

    		 NADPH Oxidase Neurological Disease Metabolic Disease
    GKT136901 hydrochloride is a potent, selective and orally active inhibitor of NADPH oxidase (NOX1/4), with Kis of 160 and 165 nM, respectively. GKT136901 hydrochloride is also a selective and direct scavenger of peroxynitrite. GKT136901 hydrochloride can be used for the research of diabetic nephropathy, stroke, and neurodegeneration. GKT136901 hydrochloride also has anti-inflammatory activity .
    GKT136901 hydrochloride
  • HY-P1387
    β-Amyloid (1-40) (rat)

    		Amyloid-β Apoptosis Neurological Disease
    β-Amyloid (1-40) (rat) is a rat form of the amyloid β-peptide, which accumulates as an insoluble extracellular deposit around neurons, giving rise to the senile plaques associated with Alzheimer's disease (AD). β-Amyloid (1-40) (rat) increases 45Ca 2+ influx, induces neurodegeneration in the rat hippocampal neurons of the CA1 subfield. β-Amyloid (1-40) (rat) induces apoptosis. β-Amyloid (1-40) (rat) can be used for the research of Alzheimer's disease .
    β-Amyloid (1-40) (rat)
  • HY-12355A
    Siponimod hemifumarate
    5+ Cited Publications

    BAF-312 hemifumarate

    		 LPL Receptor Potassium Channel Neurological Disease Inflammation/Immunology
    Siponimod (BAF-312) hemifumarate is an orally active, blood-brain barrier penetrant dual agonist of S1P1/S1P5, with EC50 values of 0.39 nM and 0.98 nM, respectively. Siponimod hemifumarate induces S1P1 internalization, activates GIRK channels, inhibits lymphocyte egress, reduces peripheral lymphocyte counts, triggers transient bradycardia, prevents synaptic neurodegeneration, promotes remyelination, alleviates demyelination, and prevents the loss of GABAergic interneurons. Siponimod hemifumarate can be used in research related to multiple sclerosis .
    Siponimod hemifumarate
  • HY-N10782
    Balanophonin

    		Apoptosis COX TNF Receptor p38 MAPK Neurological Disease Inflammation/Immunology Cancer
    Balanophonin is an anti-inflammatory and anti-cancer agent. Balanophonin inhibits microglial activation and neurodegeneration via inhibiting activated microglia-induced apoptosis .
    Balanophonin
  • HY-125172
    PolyQ aggregation inhibitor C2-8

    Polyglutamine Aggregation inhibitor III

    		 Huntingtin Others
    C2-8 is an inhibitor of polyglutamine (polyQ) aggregation (IC50s=25 and 0.05 μM for recombinant HDQ51 and in PC12 cells, respectively). It also inhibits polyQ aggregation in organotypic hippocampal slice cultures isolated from R6/2 transgenic mice and reduces neurodegeneration in a dose-dependent manner in a Drosophila model of Huntington's disease. C2-8 (100 and 200 mg/kg) reduces huntingtin aggregate size, reduces neuronal atrophy, and improves motor performance in a rotarod test in the R6/2 transgenic mouse model of Huntington's disease.
    PolyQ aggregation inhibitor C2-8
  • HY-173347
    BLINK11

    		CDK Neurological Disease
    BLINK11 is a BBB-penetrant CDK5 inhibitor. BLINK11 lowers CDK5 activity for both complexes CDK5/p35 (IC50 = 17.09 nM) and CDK5/p25 (IC50 = 14.69 nM). BLINK11 offers anti-diabetic and neuroprotective benefits. BLINK11 lowers blood glucose, enhances cognition, and reduces neurodegeneration in T2D mice .
    BLINK11
  • HY-W835959
    ACI-3024

    		Tau Protein Neurological Disease
    ACI-3024 is an an orally active and highly selective Tau protein aggregation inhibitor. ACI-3024 decrease the β-sheet content and seeding properties of pathological Tau from different Tauopathies, leading to a significant rescue of the Tau-induced neurodegeneration and neuroinflammation in a cellular model. ACI-3024 is promising for research of neurodegenerative diseases .
    ACI-3024
  • HY-176783
    GNE-5152

    		Toll-like Receptor (TLR) Neurological Disease
    GNE-5152 is an orthosteric SARM1 base-exchange (BE) inhibitor. GNE-5152 sustainably activates SARM1 at subinhibitory concentrations under mildly activating conditions, and this synergistic adverse effect increases NAD consumption, induces axon degradation and neurodegeneration and releases neurofilament-light (NfL) in cortical neurons. GNE-5152 can be used for neurodegenerative diseases research .
    GNE-5152
  • HY-151388
    hMAO-B/MB-COMT-IN-1

    		Monoamine Oxidase COMT Neurological Disease
    hMAO-B/MB-COMT-IN-1 is a dual MAO-B/MB-COMT inhibitor (IC50s: 2.5 μΜ for hMAO-B, 3.84 μΜ for MB-COMT). hMAO-B/MB-COMT-IN-1 protects cells against oxidative damage. hMAO-B/MB-COMT-IN-1 can be used in the research of neurodegeneration disease, such as Parkinson’s Disease (PD) .
    hMAO-B/MB-COMT-IN-1
  • HY-178054
    LMDP10

    		Keap1-Nrf2 Drug Derivative Neurological Disease
    LMDP10 is an orally active 3-amino quinazoline derivative with Keap1-Nrf2 pathway activation activity. LMDP10 binds to Keap1 to inhibit Keap1-Nrf2 interaction, thereby activating the Nrf2 pathway. LMDP10 elevates Nrf2, SOD, and GSH levels, reduces MDA and TNF-α levels, attenuates neurodegeneration, and improves memory function in Alzheimer’s disease (AD) rats. LMDP10 can be used for the study of AD .
    LMDP10

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: